Abstract
The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.
Keywords: HIV-1; HIV-1 and SARS-CoV-2 co-infection; ISGs; Interferon; Neutralizing antibodies; SARS-CoV-2.
【저자키워드】 Neutralizing antibodies, interferon, SARS-CoV-2., HIV-1, ISGs, HIV-1 and SARS-CoV-2 co-infection, 【초록키워드】 neutralizing antibody, SARS-CoV-2, Neutralizing antibodies, interferon, serum, Critically ill, severity of COVID-19, HIV-1, Patient, Co-infection, IFN-I, Oropharyngeal, expression, ISGs, COVID-19 patients, critically ill COVID-19 patients, IFN-α, Subtypes, infected patients, IFN-β, IFN-stimulated genes, oropharyngeal samples, males, NAb titer, greater, reported, exhibited, contribute, reduction in, 【제목키워드】 COVID-19, neutralizing antibody, Frequency, type I, patients hospitalized,